Format

Send to

Choose Destination
J Cardiovasc Transl Res. 2018 Oct;11(5):375-392. doi: 10.1007/s12265-018-9801-5. Epub 2018 Mar 19.

Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.

Author information

1
National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, 169609, Singapore.
2
National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, 169609, Singapore. ye.lei@nhcs.com.sg.

Abstract

Cardiomyocytes derived from human pluripotent stem cells (hPSCs) are emerging as an invaluable alternative to primarily sourced cardiomyocytes. The potentially unlimited number of hPSC-derived cardiomyocytes (hPSC-CMs) that may be obtained in vitro facilitates high-throughput applications like cell transplantation for myocardial repair, cardiotoxicity testing during drug development, and patient-specific disease modeling. Despite promising progress in these areas, a major disadvantage that limits the use of hPSC-CMs is their immaturity. Improvements to the maturity of hPSC-CMs are necessary to capture physiologically relevant responses. Herein, we review and discuss the different maturation strategies undertaken by others to improve the morphology, contractility, electrophysiology, and metabolism of these derived cardiomyocytes.

KEYWORDS:

Cardiomyocytes; Maturation; Pluripotent stem cells

PMID:
29557052
DOI:
10.1007/s12265-018-9801-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center